title: Genomic profiling in luminal breast cancer.
abstract: The developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.
authors.affiliation: Evangelisches Krankenhaus, Bethesda Mönchengladbach GmbH, Mönchengladbach, Germany.
authors.forename: Oleg
authors.initials: O
authors.lastname: Gluz
authors.affiliation: Evangelisches Krankenhaus, Bethesda Mönchengladbach GmbH, Mönchengladbach, Germany.
authors.forename: Daniel
authors.initials: D
authors.lastname: Hofmann
authors.affiliation: Brustzentrum, Ludwig-Maximilians-Universität München, Germany.
authors.forename: Rachel
authors.initials: R
authors.lastname: Würstlein
authors.affiliation: Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Germany.
authors.forename: Cornelia
authors.initials: C
authors.lastname: Liedtke
authors.affiliation: Evangelisches Krankenhaus, Bethesda Mönchengladbach GmbH, Mönchengladbach, Germany.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Nitz
authors.affiliation: Brustzentrum, Ludwig-Maximilians-Universität München, Germany.
authors.forename: Nadia
authors.initials: N
authors.lastname: Harbeck
keywords: Biomarker; Breast cancer; Gene expression; Luminal breast cancer; Prognostic markers